Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
CONTEXT: Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. OBJECTIVE: To update recommendations for physicians who provide HIV care regarding when to start antiretroviral therapy, what drugs to start with, when to change drug regimens, and what drug regimens to switch to after therapy fails. DATA SOURCES: Evidence was identified and reviewed by a 16-member noncompensated panel of physicians with expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care. The panel was designed to have broad US and international representation for areas with adequate access to antiretroviral management. STUDY SELECTION: Evidence considered included published basic science, clinical research, and epidemiological data (identified by experts in the field or extracted through MEDLINE searches using terms relevant to antiretroviral therapy) and abstracts from HIV-oriented scientific conferences between July 2002 and May 2004. DATA EXTRACTION: Data were reviewed to identify any information that might change previous guidelines. Based on panel discussion, guidelines were drafted by a writing committee and discussed by the panel until consensus was reached. DATA SYNTHESIS: Four antiretroviral drugs recently have been made available and have broadened the options for initial and subsequent regimens. New data allow more definitive recommendations for specific drugs or regimens to include or avoid, particularly with regard to initial therapy. Recommendations are rated according to 7 evidence categories, ranging from I (data from prospective randomized clinical trials) to VII (expert opinion of the panel). CONCLUSION: Further insights into the roles of drug toxic effects, drug resistance, and pharmacological interactions have resulted in additional guidance for strategic approaches to antiretroviral management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Self-citationvan Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U., van der Westhuizen, I., Malan, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15997-7 · Cited by 684
Self-citationEfficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Badri, M., Wilson, D., & Wood, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08904-3 · Cited by 556
Curran, J. W., Debas, H. T., Arya, M., Kelley, P., Knobler, S., & Pray, L. A. (2005) · Cited by 542
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationSexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationHammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Self-citationRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationClass-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074609 · Cited by 680
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Self-citationCost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders, G. D., Bayoumi, A. M., Sundaram, V., Bilir, S. P., Neukermans, C. P., Rydzak, C. E., Douglass, L. R., Lazzeroni, L. C., Holodniy, M., & Owens, D. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa042657 · Cited by 603
Grinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Self-citationKeeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., & Tobias, H. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.021 · Cited by 558
Montaner, J. S., Hogg, R., Wood, E., Kerr, T., Tyndall, M., Levy, A. R., & Harrigan, P. R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69162-9 · Cited by 555
Self-citationMadruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61047-2 · Cited by 517
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
Missed Visits and Mortality among Patients Establishing Initial Outpatient HIV Treatment
Mugavero, M. J., Lin, H., Willig, J. H., Westfall, A. O., Ulett, K. B., Routman, J. S., Abroms, S., Raper, J. L., Saag, M. S., & Allison, J. J. (2009) · Clinical Infectious Diseases · doi:10.1086/595705 · Cited by 481
Self-citationStellbrink, H., Orkin, C., Arribas, J. R., Compston, J., Gerstoft, J., Van Wijngaerden, E., Lazzarin, A., Rizzardini, G., Sprenger, H. G., Lambert, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/656417 · Cited by 405
Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes
Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00007 · Cited by 374
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00312-4 · Cited by 359
Eron, J., Yeni, P., Gathe, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P., Katlama, C., Young, B., Yau, L., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69155-1 · Cited by 344
Self-citationPredictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection
Rodríguez, B., Sethi, A. K., Cheruvu, V. K., Mackay, W., Bosch, R. J., Kitahata, M., Boswell, S. L., Mathews, W. C., Bangsberg, D. R., Martin, J., et al. (2006) · JAMA · doi:10.1001/jama.296.12.1498 · Cited by 320
Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., Parkin, N., & Deeks, S. G. (2006) · AIDS · doi:10.1097/01.aids.0000199825.34241.49 · Cited by 312
Rueda, S., Park-Wyllie, L. Y., Bayoumi, A., Tynan, A.-M., Antoniou, T., Rourke, S., & Glazier, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001442.pub2 · Cited by 299
The role of HIV in serious diseases other than AIDS.
Phillips, A. N., Neaton, J., & Lundgren, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3283174636 · Cited by 269
Mocroft, A., Phillips, A., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N., Losso, M., Lazzarin, A., Fatkenheuer, G., & Lundgren, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60948-9 · Cited by 259
Self-citationIntracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus
Delaney, W. E., Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., & Miller, M. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00138-06 · Cited by 259
Immunological recovery and antiretroviral therapy in HIV-1 infection
Battegay, M., Nüesch, R., Hirschel, B., & Kaufmann, G. R. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70463-7 · Cited by 255
Gupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Bartlett, J. A., Fath, M. J., DeMasi, R., Hermes, A., Quinn, J., Mondou, E., & Rousseau, F. (2006) · AIDS · doi:10.1097/01.aids.0000247578.08449.ff · Cited by 243
“recommendations regarding treatment [1,2], but”
Gulick, R. M., Su, Z., Flexner, C., Hughes, M. D., Skolnik, P. R., Wilkin, T. J., Gross, R., Krambrink, A., Coakley, E., Greaves, W. L., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/518797 · Cited by 239
Self-citationGatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., Fujimoto, K., Sato, I., Ueda, M., Horiba, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522175 · Cited by 223
Goujard, C., Bonarek, M., Meyer, L., Bonnet, F., Chaix, M.-L., Deveau, C., Sinet, M., Galimand, J., Delfraissy, J.-F., Venet, A., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/500213 · Cited by 216
“[20, 21].”
Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection
Meditz, A. L., MaWhinney, S., Allshouse, A., Feser, W., Markowitz, M., Little, S., Hecht, R., Daar, E. S., Collier, A. C., Margolick, J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq085 · Cited by 180
Self-citationBrown, J. L., & Vanable, P. A. (2008) · Annals of Behavioral Medicine · doi:10.1007/s12160-007-9010-y · Cited by 166
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
Le Tiec, C., Barrail, A., Goujard, C., & Taburet, A.-M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00003 · Cited by 159
Ceccaldi, P.-F., Gavard, L., Mandelbrot, L., Rey, E., Farinotti, R., Treluyer, J.-M., & Gil, S. (2009) · Obstetrics and Gynecology International · doi:10.1155/2009/726593 · Cited by 37
Metadata
- Authors
- Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Schooley, R. T., Thompson, M. A., Vella, S., & Volberding, P. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-07-14
- Volume
- 292
- Issue
- 2
- Pages
- 251
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2916542119
- Cited by
- 737
- References
- 34
- FWCI
- 89.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.